Le Lézard
Classified in: Health

Righttime Medical Care and HeadFirst Concussion Care Welcome Chesapeake Neurology Associates


ANNAPOLIS, Md., June 22, 2018 /PRNewswire/ -- Rightime Medical Care is pleased to announce that renowned Maryland-based neurologist Harry G. Kerasidis, M.D., and his team at Chesapeake Neurology Associates have joined the urgent care company's HeadFirst Sports Injury and Concussion Care program. Established in 1992, Chesapeake Neurology Associates see patients for a wide range of neurological and psychological evaluations and concerns including traumatic brain injury and concussion.

"Dr. Kerasidis and his outstanding clinical team are a wonderful addition to our HeadFirst program," said Righttime Chief Executive Officer and HeadFirst Medical Director Robert G. Graw, Jr., M.D. "Our highly trained providers already manage thousands of patients with head injuries every year. The addition of Chesapeake Neurology Associates truly rounds out HeadFirst to makes us a comprehensive concussion treatment center for patients of all ages."

Dr. Kerasidis received his doctor of medicine from Georgetown University where he also completed his internship and neurology residency. He was granted a fellowship in clinical neuro-physiology at Georgetown University, where his training included clinical experience in epilepsy and sleep disorders. A member of the Calvert Memorial Hospital Medical staff since 1992, Dr. Kerasidis has held several clinical leadership roles, including serving as Director of the Center for Neuroscience since it began in 2010. He is board-certified in neurology by the American Board of Psychiatry and Neurology, and is also certified by the American Board of Sleep Disorders.

Chesapeake Neurology Associates are now accepting appointments at HeadFirst clinics in Anne Arundel and Montgomery Counties.

About Righttime Medical Care and HeadFirst Sports Injury and Concussion Care
Righttime Medical Care simplifies access to trustworthy medical care at its 15 urgent care locations in Maryland. Righttime holds the Certified Urgent Care designation, which distinguishes it as among the top urgent care centers nationwide. Open 365 days a year, Righttime welcomes patients of all ages to walk-in, make a same-day appointment online at myRighttime.com or via its call center at 888-808-6483, or use its telemedicine service, RighttimeNOWtm.

As a service of Righttime Medical Care, HeadFirst Sports Injury and Concussion Care is a community concussion clinic for the diagnosis, management and treatment of mild Traumatic Brain Injuries (mTBI), helping patients of all ages make a safe return to work, school and play. HeadFirst has 11 locations in six counties in Maryland, making it one of the largest concussion programs in the country.

For more information, visit myRighttime.com and myHeadFirst.com.

Contact: Ann-Marie Sedor, [email protected], 443-332-4260 x8130

SOURCE Righttime Medical Care; HeadFirst Concussion Care


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: